For the integrated multidisciplinary approach to patient care

Return to the Southern Medical Journal

Current User S2 Access Level: -1 ()
CAN NOT ACCESS LEVEL 2

Comparative Role of Angiotensin Receptor Blockers Versus Other Agents in the Management of Hypertension, Cardiovascular Disease and Nephropathy

Michael W. Tempelhof MD
Volume: 102 Issue: 12 December, 2009

Abstract:

Article:

This content is limited to qualifying members. Please click on an option below to view in full. Click here to compare all member plans.

Login

Silver/Gold members login for full access. Other members login to view purchase options.

Create a New Account

Create a new complimentary account/login to view purchase options.

Images:

This content is limited to qualifying members. Please click on an option below to view in full. Click here to compare all member plans.

Login

Silver/Gold members login for full access. Other members login to view purchase options.

Create a New Account

Create a new complimentary account/login to view purchase options.

References:

References1. Ferrario CM. Role ofangiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006;7:3–14.FerrarioCMRole ofangiotensin II in cardiovascular disease therapeutic implications of more than a century of research.J Renin Angiotensin Aldosterone Syst200673-142. Dielis AW, Smid M, Spronk HM, et al. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension 2005;46:1236–1242.DielisAW]]SmidM]]SpronkHM&etal;The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems.Hypertension2005461236-12423. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–153.YusufS]]SleightP]]PogueJ&etal;Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.N Engl J Med2000342145-1534. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–1559.ONTARGET InvestigatorsYusufS]]TeoKK]]PogueJ&etal;Telmisartan, ramipril, or both in patients at high risk for vascular events.N Engl J Med20083581547-15595. Basile J, Toth P. Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. South Med J 2009;102(S1 online):S1–S12.BasileJ]]TothPAngiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy.South Med J2009102S1 onlineS1-S126. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.LewisEJ]]HunsickerLG]]ClarkeWR&etal;Collaborative Study GroupRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med2001345851-8607. Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–1906.PfefferMA]]McMurrayJJ]]VelazquezEJ&etal;Valsartan in Acute Myocardial Infarction Trial InvestigatorsValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.N Engl J Med20033491893-19068. Alderman MH, Ooi WL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997;10:1–8.AldermanMH]]OoiWL]]CohenH&etal;Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients.Am J Hypertens1997101-89. Rockman HA, Juneau C, Chatterjee K, et al. Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1989;64:1344–1348.RockmanHA]]JuneauC]]ChatterjeeK&etal;Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease.Am J Cardiol1989641344-134810. Parving HH, Persson F, Lewis JB, et al; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433–2446.ParvingHH]]PerssonF]]LewisJB&etal;AVOID Study InvestigatorsAliskiren combined with losartan in type 2 diabetes and nephropathy.N Engl J Med20083582433-2446

CME:

Portions of this issue may be available for CME credit. Please email education@sma.org for a complete listing of current Southern Medical Journal activities, as well as other SMA educational offerings.

This content is limited to qualifying members. Please click on an option below to view in full. Click here to compare all member plans.

Login

Silver/Gold members login for full access. Other members login to view purchase options.

Create a New Account

Create a new complimentary account/login to view purchase options.

This content is limited to qualifying members. Please click on an option below to view in full. Click here to compare all member plans.

Login

Silver/Gold members login for full access. Other members login to view purchase options.

Create a New Account

Create a new complimentary account/login to view purchase options.

Permissions